Get the Stockscreener App
17.30
1.23%
0.21
Eton Pharmaceuticals Inc stock is traded at $17.30, with a volume of 214.07K.
It is up +1.23% in the last 24 hours and up +18.57% over the past month.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
See More
Previous Close:
$17.09
Open:
$17.05
24h Volume:
214.07K
Relative Volume:
0.45
Market Cap:
$463.94M
Revenue:
$31.38M
Net Income/Loss:
$-6.69M
P/E Ratio:
-66.54
EPS:
-0.26
Net Cash Flow:
$-1.84M
1W Performance:
+1.53%
1M Performance:
+18.57%
6M Performance:
+19.23%
1Y Performance:
+307.06%
1-Day Range:
$17.02
$17.70
1-Week Range:
$15.60
$17.70
52-Week Range:
$4.23
$21.48
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
Name
Eton Pharmaceuticals Inc
Sector
Phone
(847) 787-7361
Address
21925 W. FIELD PARKWAY, DEER PARK, IL
Compare ETON with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
17.30 | 439.00M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
156.62 | 67.51B | 9.39B | 2.62B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.52 | 47.88B | 29.96B | 957.25M | 4.77B | 0.304 |
|
HLN
Haleon Plc Adr
|
9.82 | 43.42B | 14.26B | 1.98B | 2.47B | 0.4347 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
18.46 | 20.72B | 16.70B | -157.13M | 1.19B | -0.155 |
|
UTHR
United Therapeutics Corp
|
312.23 | 14.21B | 2.99B | 1.21B | 1.13B | 25.06 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-23-25 | Reiterated | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | B. Riley Securities | Buy |
| Jan-06-25 | Reiterated | H.C. Wainwright | Buy |
| Sep-04-24 | Resumed | H.C. Wainwright | Buy |
| May-06-24 | Initiated | Craig Hallum | Buy |
| Oct-14-21 | Resumed | B. Riley Securities | Buy |
| Jan-04-21 | Reiterated | H.C. Wainwright | Buy |
| Sep-20-19 | Initiated | B. Riley FBR | Buy |
| Jun-10-19 | Initiated | H.C. Wainwright | Buy |
View All
Eton Pharmaceuticals Inc Stock (ETON) Latest News
Eton Pharmaceuticals to host 1x1 meetings at 2025 Wells Fargo Healthcare Conference. - AInvest
Eton Pharmaceuticals: A Rare Disease Innovator with Strategic Momentum and Investor Appeal - AInvest
Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference - GlobeNewswire
Rare Disease Drug Developer Eton Pharmaceuticals to Meet Investors at Wells Fargo Healthcare Conference - Stock Titan
What institutional flow reveals about Eton Pharmaceuticals Inc.Portfolio Return Summary & Weekly High Return Stock Opportunities - Newser
Why Eton Pharmaceuticals Inc. is moving todayJuly 2025 Earnings & Smart Money Movement Alerts - Newser
Can Eton Pharmaceuticals Inc. recover in the next quarter2025 Winners & Losers & High Accuracy Investment Entry Signals - Newser
Smart tools for monitoring Eton Pharmaceuticals Inc.’s price actionVolume Spike & Proven Capital Preservation Methods - Newser
Live market analysis of Eton Pharmaceuticals Inc.July 2025 Institutional & Expert Approved Trade Ideas - Newser
Is Eton Pharmaceuticals Inc. trending in predictive chart modelsWeekly Profit Summary & Long Hold Capital Preservation Tips - Newser
Building trade automation scripts for Eton Pharmaceuticals Inc.Breakout Watch & Capital Efficient Trade Techniques - Newser
Chart overlay techniques for tracking Eton Pharmaceuticals Inc.2025 Buyback Activity & Verified Short-Term Trading Plans - Newser
Can technical indicators confirm Eton Pharmaceuticals Inc.’s reversalSell Signal & Growth Focused Entry Reports - Newser
Order flow analysis tools used on Eton Pharmaceuticals Inc.IPO Watch & Weekly Top Stock Performers List - Newser
Is now a turning point for Eton Pharmaceuticals Inc.2025 Retail Activity & High Accuracy Swing Entry Alerts - Newser
Will Eton Pharmaceuticals Inc. Bounce From 52 Week LowWeekly Profit Summary & Growth Focused Entry Point Reports - newsimpact.co.kr
Eton Pharma Accuses Supplement Maker of Trademark Infringement - Bloomberg Law News
Quantitative breakdown of Eton Pharmaceuticals Inc. recent moveWeekly Profit Report & Reliable Volume Spike Trade Alerts - Newser
What data driven models say about Eton Pharmaceuticals Inc.’s futureWeekly Profit Report & AI Forecast Swing Trade Picks - Newser
Is Eton Pharmaceuticals Inc. stock entering bullish territoryGap Down & Daily Risk Controlled Trade Plans - Newser
How high can Eton Pharmaceuticals Inc. stock goJuly 2025 Decliners & Community Consensus Picks - Newser
What does recent volatility data suggest for Eton Pharmaceuticals Inc.2025 Bull vs Bear & High Accuracy Trade Signal Alerts - Newser
Detecting support and resistance levels for Eton Pharmaceuticals Inc.Market Growth Report & High Conviction Investment Ideas - Newser
Signal strength of Eton Pharmaceuticals Inc. stock in tech scannersWeekly Trade Analysis & Technical Buy Zone Confirmations - Newser
Eton Pharmaceuticals Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingEarnings Performance Report & Daily Oversold Stock Bounce Ideas - Newser
Visualizing Eton Pharmaceuticals Inc. stock with heatmapsJuly 2025 Chart Watch & Daily Market Momentum Tracking - Newser
Published on: 2025-08-15 17:26:08 - Newser
What makes Eton Pharmaceuticals Inc. stock price move sharply2025 Winners & Losers & Long-Term Growth Stock Strategies - Newser
How Eton Pharmaceuticals Inc. stock reacts to Fed policy changesJuly 2025 Snapshot & AI Forecasted Entry/Exit Points - Newser
Is Eton Pharmaceuticals Inc. forming a bullish divergenceJuly 2025 Retail & Low Risk High Reward Trade Ideas - 선데이타임즈
Identifying reversal signals in Eton Pharmaceuticals Inc.2025 Valuation Update & High Accuracy Trade Alerts - Newser
XTX Topco Ltd Sells 2,858 Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Downgraded to "Hold" Rating by Wall Street Zen - MarketBeat
Published on: 2025-08-13 17:16:40 - 선데이타임즈
How to interpret RSI for Eton Pharmaceuticals Inc. stock [Gap Up]Free Low Drawdown Trading Techniques - Newser
Eton Pharmaceuticals Reports Strong Q2 Growth Amid Challenges - TipRanks
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q2 2025 Earnings Call Transcript - Insider Monkey
With 43% Ownership in Eton Pharmaceuticals, Inc. (NASDAQ:ETON), Institutional Investors Have a Lot Riding on the Business - 富途牛牛
Loss-Making Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Set To Breakeven - simplywall.st
Eton Pharmaceuticals, Inc. (ETON) Reports Q2 Loss, Tops Revenue Estimates - MSN
Eton Pharmaceuticals Experiences Record Revenue Growth and Analysts See Significant Upside Potential - AInvest
Eton targets $80M revenue run-rate in Q3 2025 as product launches accelerate - MSN
Tools to monitor Eton Pharmaceuticals Inc. recovery probabilityWeekly Breakout Forecast with Entry Zones - Newser
Is Eton Pharmaceuticals Inc. stock reversal real or fakeTrade Safety Matrix for Conservative Traders - Newser
Eton (ETON) Q2 Revenue Jumps 108% - AOL.com
Wall Street Zen Downgrades Eton Pharmaceuticals (NASDAQ:ETON) to Hold - Defense World
Published on: 2025-08-08 22:55:40 - Newser
Eton Pharmaceuticals 2025 Q2 Earnings Narrowed Losses and Strong Revenue Growth - AInvest
Eton Pharmaceuticals Inc Stock (ETON) Financials Data
Revenue
Net Income
Cash Flow
EPS
Eton Pharmaceuticals Inc Stock (ETON) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Krempa David | Chief Business Officer |
Jun 12 '25 |
Sale |
14.92 |
16,977 |
253,297 |
629,669 |
| Krempa David | Chief Business Officer |
Jun 16 '25 |
Sale |
14.73 |
10,223 |
150,585 |
612,646 |
| Krempa David | Chief Business Officer |
Jun 13 '25 |
Sale |
14.77 |
6,800 |
100,436 |
622,869 |
| Opaleye Management Inc. | 10% Owner |
Jun 10 '25 |
Buy |
15.82 |
7,930 |
125,484 |
2,770,000 |
2.37%
0.37%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):